Blog

De-risking drug development: Key chemistry, manufacturing, and controls (CMC) and physiologically based pharmacokinetic (PBPK) approaches in early development

November 22, 2024 In drug development, early strategic planning is crucial to minimizing risks, optimizing…

CertaraNovember 22, 2024

Poster

Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen

CertaraNovember 22, 2024

Poster

Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials

CertaraNovember 22, 2024

Poster

Quantitative Systems Pharmacology model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus

CertaraNovember 22, 2024

Poster

Population pharmacokinetic modeling of niraparib to assess different absorption models

CertaraNovember 22, 2024

Poster

Efficient Phase 1 Selection of CAR-T and Lymphodepletion Regimens Using Augmented Definitive Screening Design

How an augmented definitive screening design identified CAR-T and lymphodepletion regimens with 2.37-fold higher odds…

CertaraNovember 20, 2024

Publication

Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors

Find out how PopPK modelling supports precise tamibarotene dosing in pediatric and young adult solid…

CertaraNovember 14, 2024

Blog

Why clinical pharmacology & pharmacometrics should collaborate

A symbiosis between a modeler and a trialist is often required to develop a model-informed…

CertaraNovember 8, 2024

Publication

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

CertaraNovember 7, 2024

Conference

JSCPT 2026 in Japan

–

CertaraOctober 31, 2024

Clinical Pharmacology

De-risking drug development: Key chemistry, manufacturing, and controls (CMC) and physiologically based pharmacokinetic (PBPK) approaches in early development

Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen

Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials

Quantitative Systems Pharmacology model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus

Population pharmacokinetic modeling of niraparib to assess different absorption models

Efficient Phase 1 Selection of CAR-T and Lymphodepletion Regimens Using Augmented Definitive Screening Design

Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors

Why clinical pharmacology & pharmacometrics should collaborate

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

JSCPT 2026 in Japan

Newsletter sign up

Quick links

Solutions

Contact